Specifically, our data show that combining IDO1/TDO2 inhibition with chemotherapy extends the overall survival of tumor-bearing mice beyond either therapy alone, highlighting a potential clinical approach to lengthening disease-free intervals. Here, IDO1 is linked to neoplasm.